ABSTRACT
Background Accurate left ventricular outflow tract obstruction (LVOTO) assessment is crucial for hypertrophic cardiomyopathy (HCM) management and prognosis. Traditional methods often require multiple echocardiographic views, Doppler imaging, and provocation maneuvers, which may not always be feasible or readily available.
Objective To develop and validate a deep learning (DL) model capable of predicting severe LVOTO in HCM patients using only the parasternal long-axis (PLAX) view from transthoracic echocardiography (TTE).
Methods A DL model was trained on PLAX videos (developmental dataset, n=1,007) to capture both morphological and dynamic motion features for predicting severe LVOTO, generating a DL index for LVOTO (DLi-LVOTO, range 0-100). Performance was evaluated in an internal test dataset (ITDS, n=87) and externally validated in the distinct hospital dataset (DHDS, n=1,334) and the LVOTO reduction treatment dataset (n=156).
Results The DL model achieved high accuracy in detecting severe LVOTO, with an area under the receiver operating characteristics curve (AUROC) of 0.96 (95% confidence interval: 0.92-0.99) in ITDS and 0.91 (0.89-0.93) in DHDS. At a DLi-LVOTO threshold of 50, the model demonstrated high specificity 97.3% and negative predictive value (NPV) of 93.6% in ITDS, and a 92.2% specificity and 95.5% NPV in DHDS. In the LVOTO reduction treatment dataset, DLi-LVOTO showed a marked decrease following both surgical myectomy and Mavacamten treatment, correlating with reductions in peak pressure gradient (p<0.001 for all).
Conclusions Our DL-based approach predicts severe LVOTO using only the PLAX view from TTE, serving as a complementary tool when conventional Doppler evaluation is limited and for monitoring treatment response.
Competing Interest Statement
Y.E.Y, J.J., Y.J., J.K., and S.A.L. are currently affiliated with Ontact Health, Inc. J.J., J.K., and S.A.L are co-inventors on a patent related to this work filed by Ontact Health (Method for Providing Information for the Prediction of Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy). H.J.C. holds stock in Ontact Health, Inc. The other authors have no conflicts of interest to declare.
Funding Statement
This work was supported by a grant from the Institute of Information & communications Technology Planning & Evaluation (IITP) funded by the Korea government (Ministry of Science and ICT) (No.2022000972, Development of a Flexible Mobile Healthcare Software Platform Using 5G MEC); and the Medical AI Clinic Program through the NIPA funded by the MSIT. (Grant No.: H0904-24-1002).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the Institutional Review Board of Seoul National University Bundang Hospital (IRB No. B-2305-827-002, and B-2503-959-104), with a waiver of informed consent granted due to the retrospective study design. All clinical data were fully anonymized prior to analysis. The study was conducted in accordance with the principles outlined in the Declaration of Helsinki (2013).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
1. The information in the 'Declarations' section has been updated. 2. A minor typo has been corrected in the 'Abstract' section.
Data Sharing Statement
The AI-Hub data may be accessible upon proper request and after approval of a proposal. Data from TDDS cannot be made publicly available due to ethical restrictions set by the IRB of the study institution; i.e., public availability would compromise patient confidentiality and participant privacy. Please contact the corresponding author (yeonyeeyoon{at}gmail.com) to request the minimal anonymized dataset. Researchers with additional inquiries about the deep learning model developed in this study are also encouraged to reach out to the corresponding author.
